{"id":"heptavalent-pneumococcal-conjugate-vaccine-prevenar","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, or swelling at the injection site"},{"rate":"null","effect":"Fever"},{"rate":"null","effect":"Irritability"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The heptavalent pneumococcal conjugate vaccine, Prevenar, works by introducing antigens from seven serotypes of Streptococcus pneumoniae to the body, which triggers an immune response and the production of antibodies. These antibodies help to neutralize the bacteria and prevent infection. The vaccine is designed to provide protection against invasive pneumococcal disease, such as meningitis and sepsis, as well as non-invasive diseases like pneumonia.","oneSentence":"Prevenar stimulates the body's immune system to produce antibodies against pneumococcal disease.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:47:51.765Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of invasive pneumococcal disease caused by seven serotypes of Streptococcus pneumoniae"}]},"trialDetails":[{"nctId":"NCT07242092","phase":"PHASE4","title":"Influence of Methotrexate Discontinuation on Immunogenicity After PCV-20 Vaccine in Patients ARDs","status":"NOT_YET_RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-03-25","conditions":"Autoimmune Rheumatic Diseases","enrollment":192},{"nctId":"NCT04460313","phase":"NA","title":"Nasopharyngeal Carriage of S. Pneumoniae","status":"RECRUITING","sponsor":"Association Clinique Thérapeutique Infantile du val de Marne","startDate":"2001-09-11","conditions":"Nasopharyngeal Carriage, Children, Only, Antibiotic Resistant Strain","enrollment":25760},{"nctId":"NCT07425392","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Prior Pneumococcal Vaccination","status":"RECRUITING","sponsor":"Vaxcyte, Inc.","startDate":"2026-02-09","conditions":"Pneumococcal Vaccines","enrollment":720},{"nctId":"NCT06077656","phase":"PHASE2","title":"Dose-Ranging Study to Evaluate a 25-Valent Pneumococcal Conjugate Vaccine","status":"COMPLETED","sponsor":"Inventprise Inc.","startDate":"2023-10-25","conditions":"Pneumococcal Vaccines","enrollment":220},{"nctId":"NCT07284654","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of VAX-31 in Adults ≥50 Years With Immunobridging to Adults 18-49","status":"RECRUITING","sponsor":"Vaxcyte, Inc.","startDate":"2025-12-01","conditions":"Pneumococcal Vaccines","enrollment":4000},{"nctId":"NCT07023081","phase":"PHASE1","title":"A Study to Understand the Safety of the 20vPnC Vaccine in Healthy Chinese Adults, Children, and Infant","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2025-06-15","conditions":"Pneumococcal Disease","enrollment":200},{"nctId":"NCT06622109","phase":"","title":"A Study to Learn About the Safety of PREVENAR 20 Vaccine in Infants Aged Between Two to Six Months","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-11-25","conditions":"Pneumococcal Disease","enrollment":1100},{"nctId":"NCT06782282","phase":"","title":"A Study to Learn About How Well the Prevnar 20 Vaccine Works for Pneumonia in People Who Are 65 Years and Older","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2025-01-20","conditions":"Community-Acquired Pneumonia (CAP)","enrollment":22234435},{"nctId":"NCT06531538","phase":"PHASE2","title":"A Study to Learn About How a New Pneumococcal Vaccine Works in Children","status":"COMPLETED","sponsor":"Pfizer","startDate":"2024-07-30","conditions":"Pneumococcal Disease","enrollment":225},{"nctId":"NCT03650114","phase":"PHASE3","title":"Long-term Safety, Tolerability and Effectiveness Study of Ofatumumab in Patients With Relapsing MS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2018-12-28","conditions":"Relapsing Multiple Sclerosis","enrollment":1882},{"nctId":"NCT07365826","phase":"PHASE3","title":"A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 With Influenza Vaccine in Adults ≥ 50 Years of Age","status":"RECRUITING","sponsor":"Vaxcyte, Inc.","startDate":"2026-01-12","conditions":"Pneumococcal Vaccines","enrollment":1300},{"nctId":"NCT06049134","phase":"PHASE4","title":"Immunogenicity and Clinical Efficacy of 20-valent Pneumococcal Conjugate Vaccine (PCV20) in Lymphoma Survivors After Treatment With Anti-CD20 Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2023-10-06","conditions":"Lymphoma","enrollment":30},{"nctId":"NCT07252791","phase":"PHASE4","title":"Safety and Immunogenicity of PCV20 in Pediatric Patients With Autoimmune Rheumatic Diseases","status":"RECRUITING","sponsor":"University of Sao Paulo General Hospital","startDate":"2026-01-16","conditions":"Autoimmune Rheumatologic Disease","enrollment":114},{"nctId":"NCT06128915","phase":"PHASE4","title":"The Role of Neutrophils in the Age-driven Decline in Anti-pneumococcal Vaccine Responses","status":"RECRUITING","sponsor":"State University of New York at Buffalo","startDate":"2024-01-08","conditions":"Aging","enrollment":60},{"nctId":"NCT06824194","phase":"PHASE3","title":"Study of the Safety of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"RECRUITING","sponsor":"Sanofi","startDate":"2025-02-18","conditions":"Pneumococcal Immunization","enrollment":2320},{"nctId":"NCT06975878","phase":"PHASE3","title":"Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-05-22","conditions":"Pneumococcal Immunization, Healthy Volunteers","enrollment":1092},{"nctId":"NCT07017777","phase":"PHASE3","title":"A Study to Evaluate the Immunogenicity and Safety of 13-valent Pneumococcal Conjugate Vaccine (PCV13i) in Healthy Infants Aged 2 Months (Minimum 6 Weeks)","status":"RECRUITING","sponsor":"CanSino Biologics Inc.","startDate":"2025-11-14","conditions":"Pneumococcal Infections, Streptococcal Infections, Bacterial Infections","enrollment":600},{"nctId":"NCT07019909","phase":"PHASE1","title":"A Study to Learn About How Safe and Effective is 20vPnC and 13vPnC Vaccines in Chinese Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2025-07-06","conditions":"Pneumococcal Disease","enrollment":400},{"nctId":"NCT07348692","phase":"PHASE3","title":"Lot-to-lot Consistency Study of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From 2 Months of Age","status":"RECRUITING","sponsor":"Sanofi","startDate":"2026-01-20","conditions":"Pneumococcal Immunization, Healthy Volunteers","enrollment":896},{"nctId":"NCT07428759","phase":"PHASE1","title":"Trial to Evaluate Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults Aged 50 To 64 Years","status":"NOT_YET_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2026-03-10","conditions":"Pneumonia, Bacterial","enrollment":120},{"nctId":"NCT06736041","phase":"PHASE3","title":"Study of a 4-Dose Regimen of a 21-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2024-12-18","conditions":"Pneumococcal Immunization","enrollment":1714},{"nctId":"NCT06824181","phase":"PHASE3","title":"Study of Mixed Vaccination Schedules With a 21-valent Pneumococcal Conjugate Vaccine and a 20-valent Pneumococcal Conjugate Vaccine in Healthy Infants From Approximately 2 Months of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-02-27","conditions":"Pneumococcal Immunization","enrollment":580},{"nctId":"NCT05170399","phase":"PHASE4","title":"Vaccine Responses in Patients With B Cell Malignancies","status":"RECRUITING","sponsor":"National Heart, Lung, and Blood Institute (NHLBI)","startDate":"2022-09-14","conditions":"Lymphoma","enrollment":500},{"nctId":"NCT04745559","phase":"PHASE2","title":"Optimizing Cellular and Humoral Immunity by Vaccinating With PCV13 Before and After CAR-T Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2021-02-18","conditions":"Diffuse Large-Cell Lymphoma, Primary Mediastinal Large B-Cell Lymphoma (PMBCL), Transformed Follicular Lymphoma (TFL)","enrollment":26},{"nctId":"NCT07247188","phase":"PHASE3","title":"Study of a Single Dose of a 21-valent Pneumococcal Conjugate Vaccine in Children and Adolescents With Sickle Cell Disease","status":"RECRUITING","sponsor":"Sanofi","startDate":"2026-01-20","conditions":"Sickle Cell Disease","enrollment":100},{"nctId":"NCT06550830","phase":"PHASE1","title":"Clinical Trial of PCV24 in Children Aged 2-17 Years","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2024-09-07","conditions":"Pneumococcal Infectious Disease","enrollment":119},{"nctId":"NCT06800261","phase":"PHASE1","title":"Clinical Trial of PCV24 in Infants Aged 2-23 Months","status":"RECRUITING","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2025-05-08","conditions":"Pneumococcal Infectious Disease","enrollment":180},{"nctId":"NCT06617715","phase":"PHASE3","title":"Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine","status":"RECRUITING","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2024-10-23","conditions":"Pneumococcal Infectious Disease","enrollment":3080},{"nctId":"NCT05452941","phase":"","title":"A Study to Learn About How 20-Valent Pneumococcal Conjugate Vaccine Works in a Real-world Setting","status":"RECRUITING","sponsor":"Pfizer","startDate":"2022-10-27","conditions":"Pneumonia","enrollment":12500},{"nctId":"NCT06720038","phase":"PHASE2","title":"A Clinical Study to Evaluate the Safety, Tolerability, and Immunogenicity of VAX-31 in Healthy Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vaxcyte, Inc.","startDate":"2024-11-25","conditions":"Pneumococcal Vaccines","enrollment":905},{"nctId":"NCT07105722","phase":"PHASE1","title":"A Trial to Evaluate the Safety and Immune Response of an Investigational Pneumococcal Vaccine in Adults 50 To 64 Years of Age","status":"ACTIVE_NOT_RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-08-12","conditions":"Pneumonia, Bacterial","enrollment":127},{"nctId":"NCT07300644","phase":"PHASE2","title":"Clinical Trial of PCV24 in Infants and Children Aged 2 Months to 5 Years","status":"RECRUITING","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2025-11-25","conditions":"Pneumococcal Infectious Disease","enrollment":420},{"nctId":"NCT06822907","phase":"PHASE4","title":"Immunogenicity and Safety PCV-20 of the Vaccine Administered During an Acute Febrile Illness in Adults","status":"NOT_YET_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Saint Etienne","startDate":"2026-01","conditions":"Acute Febrile Illness, Pneumococcal Infections","enrollment":1052},{"nctId":"NCT06817421","phase":"PHASE4","title":"Opportunistic Pneumococcal Immunisation Trial in MALnutrition","status":"NOT_YET_RECRUITING","sponsor":"Nick Fancourt","startDate":"2026-01","conditions":"Severe Acute Malnutrition in Childhood, Pneumococcal Disease, Pneumococcal Vaccines","enrollment":214},{"nctId":"NCT05512819","phase":"PHASE3","title":"A Study to Describe the Safety and Immunogenicity of 20vPnC in Infants in India and Taiwan","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-09-16","conditions":"Pneumococcal Disease","enrollment":541},{"nctId":"NCT06806137","phase":"PHASE3","title":"A Study on the Immune Response and Safety of the Second Dose of an Investigational Chickenpox Vaccine When Given to Healthy Children 3 Months After a First Dose at 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-05-15","conditions":"Chickenpox","enrollment":600},{"nctId":"NCT06855160","phase":"PHASE3","title":"A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine and a Marketed Measles, Mumps and Rubella Vaccine When Administered as Intramuscular Injection to Healthy Children 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-04-17","conditions":"Chickenpox","enrollment":900},{"nctId":"NCT03069703","phase":"PHASE2","title":"Innovative Anti-pneumococcal Vaccine Strategies in Patients With ANCA-associated Vasculitis Receiving Rituximab Therapy","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-02-05","conditions":"Invasive Pneumococcal Infection","enrollment":96},{"nctId":"NCT07135427","phase":"PHASE4","title":"Genetic Variation in IgG in Alpha 1 Antitrypsin Deficiency","status":"RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2025-09-03","conditions":"Alpha 1-Antitrypsin, COPD, Antibody Deficiency","enrollment":30},{"nctId":"NCT05794191","phase":"","title":"A Study To Learn About The Effects Of Pneumococcal Vaccine In People With HIV","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-03-22","conditions":"HIV, Pneumonia, Infections, Pneumococcal","enrollment":350399},{"nctId":"NCT06182124","phase":"PHASE1, PHASE2","title":"A Study to Learn About the Safety and Immune Response of a New Pneumococcal Vaccine in Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2023-12-20","conditions":"Pneumococcal Disease","enrollment":558},{"nctId":"NCT06838000","phase":"PHASE3","title":"Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) in Healthy Infants, Toddlers, Children, and Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2025-02-28","conditions":"Pneumococcal Infections","enrollment":1268},{"nctId":"NCT05844423","phase":"PHASE2","title":"Safety, Tolerability, and Immunogenicity of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Healthy Infants","status":"COMPLETED","sponsor":"Vaxcyte, Inc.","startDate":"2023-03-29","conditions":"Pneumococcal Vaccines","enrollment":802},{"nctId":"NCT00611663","phase":"PHASE2, PHASE3","title":"Safety Study of Two Vaccine Strategies in Patients With Systemic Lupus Erythematosus","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2008-05","conditions":"Lupus Erythematosus, Systemic","enrollment":47},{"nctId":"NCT04583618","phase":"PHASE2","title":"Study of a Pneumococcal Conjugate Vaccine in Adults Aged 50 to 84 Years.","status":"COMPLETED","sponsor":"Sanofi","startDate":"2020-10-08","conditions":"Pneumococcal Immunization","enrollment":750},{"nctId":"NCT04398706","phase":"PHASE2","title":"Study of a Pneumococcal Conjugate Vaccine When Administered Concomitantly With Routine Pediatric Vaccines in Healthy Toddlers and Infants","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2020-05-22","conditions":"Pneumococcal Immunisation, Diphtheria Immunisation, Tetanus Immunisation","enrollment":852},{"nctId":"NCT06524414","phase":"PHASE2","title":"A Study to Learn About How a New Pneumococcal Vaccine Works in Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-07-25","conditions":"Pneumococcal Disease","enrollment":605},{"nctId":"NCT04078997","phase":"","title":"An Evaluation of PCV13 Vaccine Schedules, Comparing Impact of 2+1 vs 3+0 on Pneumococcal Carriage in Blantyre, Malawi","status":"COMPLETED","sponsor":"University of Liverpool","startDate":"2019-07-21","conditions":"13-valent Pneumococcal Vaccine, Streptococcus Pneumoniae","enrollment":3507},{"nctId":"NCT06790290","phase":"PHASE2","title":"Phase 2 Trial to Evaluate Safety and Immunogenicity of Inventprise's (IVT) 25-valent Pneumococcal Conjugate Vaccine (IVT PCV-25) in Healthy Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Inventprise Inc.","startDate":"2025-01-27","conditions":"Pneumococcal Disease, Invasive","enrollment":421},{"nctId":"NCT06271681","phase":"PHASE4","title":"Evaluation of PCV21 Vaccination Among PPSV23-experienced, Immunocompromised Elderly Veterans","status":"NOT_YET_RECRUITING","sponsor":"VA Sierra Nevada Health Care System","startDate":"2026-01-01","conditions":"Pneumococcal Vaccines, Immunosuppression","enrollment":45},{"nctId":"NCT07086677","phase":"PHASE1","title":"A Study to Learn About How a New Pneumococcal Vaccine Works in Adults","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-07-22","conditions":"Streptococcus Pneumoniae","enrollment":372},{"nctId":"NCT06879327","phase":"PHASE2","title":"Infant Malaria Vaccine Schedule Optimization","status":"RECRUITING","sponsor":"PATH","startDate":"2025-05-30","conditions":"Malaria Vaccines","enrollment":1200},{"nctId":"NCT06151288","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, and Immunogenicity Study of a 31-Valent Pneumococcal Conjugate Vaccine (VAX-31) in Adults","status":"COMPLETED","sponsor":"Vaxcyte, Inc.","startDate":"2023-11-08","conditions":"Pneumococcal Vaccines","enrollment":1015},{"nctId":"NCT05158140","phase":"PHASE3","title":"Safety, Tolerability, and Immunogenicity of V110 or V114 Co-administered With a Booster Dose of mRNA-1273 in Healthy Adults (V110-911)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2022-01-12","conditions":"Pneumococcal Infection","enrollment":850},{"nctId":"NCT04613375","phase":"","title":"PCV13 Effectiveness Study Against Hospitalised VT Pneumococcal CAP in Adults 60 Years and Older","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-03-12","conditions":"Community Acquired Pneumonia (CAP)","enrollment":1821},{"nctId":"NCT00622843","phase":"PHASE3","title":"Pneumococcal Conjugate Vaccination in HIV in Comparison to Polysaccharide Vaccine Boosting","status":"COMPLETED","sponsor":"Henry M. Jackson Foundation for the Advancement of Military Medicine","startDate":"2002-12","conditions":"HIV Infections, Streptococcus Pneumoniae","enrollment":275},{"nctId":"NCT04945681","phase":"PHASE4","title":"Evaluating the Effectiveness of a Pneumococcal Immunisation Campaign in a Camp for Internally Displaced People","status":"ACTIVE_NOT_RECRUITING","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2022-11-27","conditions":"Pneumococcal Infections","enrollment":2882},{"nctId":"NCT06986239","phase":"PHASE1","title":"Safety and Immunogenicity of PCV-LITE, a Low-dose of Pneumococcal Conjugate Vaccine With LiteVax Adjuvant","status":"NOT_YET_RECRUITING","sponsor":"LiteVax BV","startDate":"2025-07-01","conditions":"Vaccine Reaction","enrollment":80},{"nctId":"NCT06970756","phase":"PHASE1","title":"A Phase I Clinical Study to Evaluate the Safety of PCV26 in Individuals ≥60","status":"NOT_YET_RECRUITING","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2025-05-27","conditions":"Pneumococcal Diseases","enrollment":60},{"nctId":"NCT05879107","phase":"PHASE3","title":"Study to Assess the Immune Response, the Safety and the Reactogenicity of Respiratory Syncytial Virus (RSV) Prefusion Protein 3 Older Adult (OA) (RSVPreF3 OA) Investigational Vaccine When co Administered With PCV20 in Older Adults","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2023-05-26","conditions":"Respiratory Syncytial Virus Infections","enrollment":1113},{"nctId":"NCT06562790","phase":"PHASE1","title":"Study of Gamma PN3 in the Elderly","status":"COMPLETED","sponsor":"GPN Vaccines","startDate":"2024-08-26","conditions":"Pneumonia, Pneumococcal","enrollment":105},{"nctId":"NCT06474377","phase":"PHASE1","title":"Clinical Trial of PCV24 in Adults","status":"COMPLETED","sponsor":"Sinovac Life Sciences Co., Ltd.","startDate":"2024-06-21","conditions":"Pneumococcal Infectious Disease","enrollment":170},{"nctId":"NCT01527591","phase":"NA","title":"Pneumococcal Conjugate Vaccine 13 (Prevnar13®) in Children Who Are Solid Organ Transplant Recipients (SOT)","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2012-02-01","conditions":"Infection in Solid Organ Transplant Recipients","enrollment":17},{"nctId":"NCT06740630","phase":"PHASE3","title":"A Study on the Immune Response and Safety of an Investigational Chickenpox Vaccine When Given to Healthy Children 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2025-01-10","conditions":"Chickenpox","enrollment":1840},{"nctId":"NCT03547271","phase":"PHASE3","title":"Immunogenicity and Safety Study of a Quadrivalent Meningococcal Conjugate Vaccine When Co-administered With Routine Pediatric Vaccines in Healthy Infants and Toddlers in Europe","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-12-14","conditions":"Meningococcal Infections","enrollment":1660},{"nctId":"NCT05084508","phase":"PHASE2","title":"A Study on the Immune Response and Safety of Various Potencies of an Investigational Chickenpox Vaccine Compared With a Marketed Chickenpox Vaccine, Given to Healthy Children 12 to 15 Months of Age","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2022-02-03","conditions":"Chickenpox","enrollment":800},{"nctId":"NCT06817187","phase":"PHASE3","title":"Clinical Study on the Combined Administration of 15-Valent Pneumococcal Conjugate Vaccine and Diphtheria, Tetanus, Pertussis Vaccine","status":"COMPLETED","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2021-09-16","conditions":"Streptococcus Pneumoniae Infections","enrollment":1110},{"nctId":"NCT06813729","phase":"PHASE4","title":"Effects of Shotblocker® and Manual Pressure on Pain","status":"COMPLETED","sponsor":"Aydin Adnan Menderes University","startDate":"2022-02-15","conditions":"Healthy Volunteers, Infant, Vaccine","enrollment":102},{"nctId":"NCT06703203","phase":"PHASE1, PHASE2","title":"Phase I/II Clinical Trial of 26-valent Pneumococcal Conjugate Vaccine","status":"ENROLLING_BY_INVITATION","sponsor":"Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd","startDate":"2024-08-27","conditions":"Pneumococcal Vaccines","enrollment":450},{"nctId":"NCT06693895","phase":"PHASE3","title":"A Study on the Safety of an Investigational Chickenpox Vaccine, When Given to Healthy Children, 12 to 15 Months of Age","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-11-26","conditions":"Chickenpox","enrollment":750},{"nctId":"NCT03848065","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity of V114 in Healthy Japanese Infants (V114-028)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2019-04-02","conditions":"Pneumococcal Infections","enrollment":133},{"nctId":"NCT01926860","phase":"PHASE4","title":"PCV13 + Hepatitis a Vaccine for Adults","status":"COMPLETED","sponsor":"Helsinki University Central Hospital","startDate":"2013-08-24","conditions":"Measurement of Immune Response to Prevenar13, Measurement of Immune Response to Hepatitis a","enrollment":305},{"nctId":"NCT03098628","phase":"PHASE2, PHASE3","title":"Trial of Simplified Pneumococcal Vaccination in Vietnam II","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2017-03-08","conditions":"Pneumococcal Vaccine","enrollment":2501},{"nctId":"NCT06698198","phase":"PHASE1","title":"Safety and Immunogenicity of a Pneumococcal Conjugate Vaccine Candidate in Healthy Adults (19-49 Years)","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2018-12-03","conditions":"Pneumococcal Immunization","enrollment":175},{"nctId":"NCT03489018","phase":"PHASE4","title":"The Effect of Fractional Doses of Pneumococcal Conjugate Vaccines on Immunogenicity and Carriage in Kenyan Infants","status":"COMPLETED","sponsor":"London School of Hygiene and Tropical Medicine","startDate":"2019-03-21","conditions":"Pneumococcal Infection, Streptococcus Pneumoniae Infection, Invasive Pneumococcal Disease, Protection Against","enrollment":2100},{"nctId":"NCT03574389","phase":"PHASE3","title":"A Study Assessing 13-valent Pneumococcal Conjugate Vaccine in Healthy Chinese Infants and Young Children","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-06-23","conditions":"Pneumococcal Infections, Pneumococcal Conjugate Vaccine","enrollment":936},{"nctId":"NCT04875533","phase":"PHASE3","title":"20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study in Pneumococcal Vaccine-Naïve Adults 60 Years of Age and Older in Japan, Korea, and Taiwan","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-06-14","conditions":"Pneumococcal Disease","enrollment":1425},{"nctId":"NCT05875727","phase":"PHASE3","title":"A Study to Learn About the Safety and Immune Response of 20vPnC in Adults in India.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-08-16","conditions":"Pneumococcal Disease","enrollment":405},{"nctId":"NCT05297578","phase":"PHASE2","title":"Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Older Adults","status":"COMPLETED","sponsor":"Vaxcyte, Inc.","startDate":"2022-06-15","conditions":"Pneumococcal Vaccines","enrollment":207},{"nctId":"NCT05759520","phase":"PHASE3","title":"Phase III Clinical Trial of 13-valent Pneumococcal Conjugate Vaccine (Multivalent Conjugate) in Infants","status":"ACTIVE_NOT_RECRUITING","sponsor":"Fosun Adgenvax Biopharmaceutical Co.,Ltd.","startDate":"2022-11-04","conditions":"Streptococcus Pneumoniae Infection","enrollment":1800},{"nctId":"NCT04633226","phase":"PHASE3","title":"Safety and Immunogenicity of V114 in Healthy Infants in South Korea (V114-036)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2021-02-10","conditions":"Pneumococcal Disease","enrollment":58},{"nctId":"NCT05408429","phase":"PHASE3","title":"Safety and Immunogenicity of 20vPnC in Toddlers With 2 Prior Doses of Prevenar 13","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-06-24","conditions":"Pneumococcal Disease","enrollment":356},{"nctId":"NCT04275284","phase":"","title":"Persistence of Immunogenicity Following Reduced PCV Dosing Schedules in South African Children","status":"COMPLETED","sponsor":"University of Witwatersrand, South Africa","startDate":"2020-02-14","conditions":"Pneumonia, Meningitis","enrollment":600},{"nctId":"NCT05831124","phase":"PHASE1","title":"A Study to Learn About a Type of Pneumococcal Vaccine With a New Ingredient (PF-07872411) Intended to Enhance the Effects of the Vaccine Which is Given to Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-04-19","conditions":"Pneumococcal Disease","enrollment":90},{"nctId":"NCT05934890","phase":"PHASE3","title":"A Phase 3 Study to Evaluate the Immunogenicity and Safety of Walvax's PCV13-TT as Compared to Pfizer's PCV13","status":"ACTIVE_NOT_RECRUITING","sponsor":"Walvax Biotechnology Co., Ltd.","startDate":"2023-11-23","conditions":"Pneumococcal Disease, Invasive","enrollment":630},{"nctId":"NCT06450379","phase":"","title":"Impact of Vaccines on Antimicrobial Microbial Resistance","status":"COMPLETED","sponsor":"Malawi Liverpool Wellcome Programme","startDate":"2021-03-15","conditions":"Vaccine","enrollment":13200},{"nctId":"NCT05329259","phase":"PHASE4","title":"A Study to Describe the Safety of a Vaccine (Called 13vPnC) in Healthy People 18 to 49 Years of Age in India","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-10-06","conditions":"Pneumococcal Disease","enrollment":200},{"nctId":"NCT02961231","phase":"PHASE4","title":"Evaluation of PCV Schedules in a Naive Population in Vietnam","status":"COMPLETED","sponsor":"Nagasaki University","startDate":"2016-10-01","conditions":"Pneumonia, Pneumococcal","enrollment":18652},{"nctId":"NCT05489328","phase":"PHASE1","title":"Safety and Immunogenicity of Pneumococcal Conjugate Formulations in Healthy Adults 18 Through 49 Years of Age","status":"COMPLETED","sponsor":"Pfizer","startDate":"2022-08-15","conditions":"Pneumococcal Disease","enrollment":394},{"nctId":"NCT05266456","phase":"PHASE1, PHASE2","title":"Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults","status":"COMPLETED","sponsor":"Vaxcyte, Inc.","startDate":"2022-02-22","conditions":"Pneumococcal Vaccines","enrollment":835},{"nctId":"NCT04841369","phase":"PHASE3","title":"Phase III Clinical Trial of a Candidate PCV13 in Healthy People Aged 6 Weeks and Above (PICTPCV13i)","status":"COMPLETED","sponsor":"CanSino Biologics Inc.","startDate":"2021-04-13","conditions":"Pneumococcal Infections, Streptococcal Infections, Bacterial Infections","enrollment":3420},{"nctId":"NCT03384589","phase":"PHASE2, PHASE3","title":"CIRN Pneumococcal Conjugate Vaccine 1 vs. 2 Dose Priming Study","status":"COMPLETED","sponsor":"University of British Columbia","startDate":"2018-08-23","conditions":"Invasive Pneumococcal Disease, Protection Against, Streptococcus Pneumoniae Infection","enrollment":248},{"nctId":"NCT05274607","phase":"","title":"Pneumonia and Empyema in Emergency Departments in Children","status":"UNKNOWN","sponsor":"Association Clinique Thérapeutique Infantile du val de Marne","startDate":"2009-06-01","conditions":"Pneumonia, Pleural Effusion","enrollment":20000},{"nctId":"NCT04642079","phase":"PHASE3","title":"Safety and Immunogenicity Study of 20vPnC in Healthy Children 15 Months Through 17 Years of Age","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-12-04","conditions":"Pneumococcal Disease","enrollment":839},{"nctId":"NCT06213506","phase":"PHASE2","title":"A Study on the Safety, Reactogenicity, and Immune Response to the GVGH iNTS-GMMA Vaccine Against Invasive Nontyphoidal Salmonella in Adults, Children, and Infants","status":"RECRUITING","sponsor":"GlaxoSmithKline","startDate":"2024-01-15","conditions":"Salmonella Infections","enrollment":516},{"nctId":"NCT04923035","phase":"","title":"Paediatric Pneumococcal Pneumonia in Malaysia Prior to and During Pneumococcal Conjugate Vaccine (PCV) Implementation","status":"UNKNOWN","sponsor":"IMU University, Malaysia","startDate":"2021-10-13","conditions":"Pneumonia, Pneumococcal, Pneumonia Childhood","enrollment":1010},{"nctId":"NCT04546425","phase":"PHASE3","title":"20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 3-Dose Series in Healthy Infants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-09-09","conditions":"Pneumococcal Disease","enrollment":1258},{"nctId":"NCT04382326","phase":"PHASE3","title":"20-valent Pneumococcal Conjugate Vaccine Safety and Immunogenicity Study of a 4-Dose Series in Healthy Infants","status":"COMPLETED","sponsor":"Pfizer","startDate":"2020-05-20","conditions":"Pneumococcal Disease","enrollment":1997},{"nctId":"NCT02637583","phase":"PHASE4","title":"Sequential Versus Simultaneous Pneumococcal Vaccination in Elderly: Immunological Memory and Antibody Levels","status":"COMPLETED","sponsor":"Jena University Hospital","startDate":"2017-10-18","conditions":"Pneumococcal Infections","enrollment":123},{"nctId":"NCT03900520","phase":"","title":"Pneumonia Research and Vaccine Impact League","status":"COMPLETED","sponsor":"Johns Hopkins Bloomberg School of Public Health","startDate":"2020-10-13","conditions":"Pneumonia","enrollment":6004}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":11,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"heptavalent pneumococcal conjugate vaccine, Prevenar","genericName":"heptavalent pneumococcal conjugate vaccine, Prevenar","companyName":"Heinrich-Heine University, Duesseldorf","companyId":"heinrich-heine-university-duesseldorf","modality":"Biologic","firstApprovalDate":"","aiSummary":"Prevenar stimulates the body's immune system to produce antibodies against pneumococcal disease. Used for Prevention of invasive pneumococcal disease caused by seven serotypes of Streptococcus pneumoniae.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}